Smith Hayes Advisers’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Smith Hayes Advisers’s Portfolio FBT Stock Details FBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,753	Closed	-$537K	–	308
2015 Q4	$537K	Sell	4,753 -391	-8%	-$42.1K	0.11%	189
2015 Q3	$521K	Sell	5,144 -555	-10%	-$66K	0.11%	182
2015 Q2	$707K	Sell	5,699 -2,071	-27%	-$250K	0.14%	164
2015 Q1	$919K	Sell	7,770 -616	-7%	-$69.6K	0.18%	141
2014 Q4	$855K	Buy	8,386 +1	+0%	+$98	0.18%	147
2014 Q3	$770K	Sell	8,385 -8,092	-49%	-$702K	0.18%	139
2014 Q2	$1.36M	Buy	16,477 +525	+3%	+$40.1K	0.32%	98
2014 Q1	$1.22M	Buy	15,952 +4,123	+35%	+$322K	0.3%	103
2013 Q4	$818K	Buy	11,829 +7,473	+172%	+$490K	0.27%	114
2013 Q3	$282K	Buy	+4,356	New	+$276K	0.11%	191

Other funds holding FBT

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Smith Hayes Advisers's FBT Position: Q1 2016 in Review

Smith Hayes Advisers sold out of First Trust NYSE Arca Biotechnology Index Fund (FBT) in Q1 2016, closing a stake of 4,753 shares — an estimated $537K sold.

Smith Hayes Advisers first reported a position in FBT in Q3 2013 and held it in 10 quarters. The position peaked at $1.36M in Q2 2014. 107 funds tracked by Wall St. Rank hold FBT as of Q1 2016.

Smith Hayes Advisers reported no remaining First Trust NYSE Arca Biotechnology Index Fund position as of Q1 2016 after selling out during the quarter.
Smith Hayes Advisers sold 4,753 First Trust NYSE Arca Biotechnology Index Fund shares in Q1 2016, an estimated $537K.
Smith Hayes Advisers first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q3 2013 and held it in 10 quarters.
Smith Hayes Advisers's First Trust NYSE Arca Biotechnology Index Fund position peaked at $1.36M in Q2 2014.
107 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q1 2016.

Based on Smith Hayes Advisers's 13F filing for Q1 2016, filed 16 May 2016.